Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.35
CLVS's Cash to Debt is ranked lower than
77% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. CLVS: 1.35 )
Ranked among companies with meaningful Cash to Debt only.
CLVS' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: No Debt Max: No Debt
Current: 1.35
F-Score: 1
Z-Score: -3.14
M-Score: -5.23
WACC vs ROIC
10.62%
-624.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -170.97
CLVS's ROE (%) is ranked lower than
90% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CLVS: -170.97 )
Ranked among companies with meaningful ROE (%) only.
CLVS' s ROE (%) Range Over the Past 10 Years
Min: -170.97  Med: -55.78 Max: -26.78
Current: -170.97
-170.97
-26.78
ROA (%) -63.73
CLVS's ROA (%) is ranked lower than
77% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CLVS: -63.73 )
Ranked among companies with meaningful ROA (%) only.
CLVS' s ROA (%) Range Over the Past 10 Years
Min: -144.39  Med: -49.23 Max: -21.25
Current: -63.73
-144.39
-21.25
ROC (Joel Greenblatt) (%) -11191.98
CLVS's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. CLVS: -11191.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11191.98  Med: -6626.76 Max: -3834.63
Current: -11191.98
-11191.98
-3834.63
EBITDA Growth (3Y)(%) 51.80
CLVS's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CLVS: 51.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.4  Med: -31.4 Max: 51.8
Current: 51.8
-53.4
51.8
EPS Growth (3Y)(%) 48.80
CLVS's EPS Growth (3Y)(%) is ranked higher than
91% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. CLVS: 48.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.1  Med: -31.1 Max: 48.8
Current: 48.8
-53.1
48.8
» CLVS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CLVS Guru Trades in Q3 2015

Jim Simons 128,900 sh (New)
Andreas Halvorsen 836,332 sh (New)
Paul Tudor Jones 4,131 sh (New)
Steven Cohen 117,100 sh (unchged)
» More
Q4 2015

CLVS Guru Trades in Q4 2015

Paul Tudor Jones 225,000 sh (+5346.62%)
Steven Cohen 117,100 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
» More
Q1 2016

CLVS Guru Trades in Q1 2016

Kyle Bass 100,000 sh (New)
Jim Simons 515,400 sh (New)
Steven Cohen 603,100 sh (unchged)
Paul Tudor Jones 13,858 sh (-93.84%)
» More
Q2 2016

CLVS Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Kyle Bass Sold Out
Jim Simons 307,200 sh (-40.40%)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RLYP, OTCPK:AKBLF, NAS:FGEN, NAS:XLRN, NAS:SAGE, NYSE:CBM, NAS:INVA, NAS:AAAP, OTCPK:SXMDF, NYSE:AXON, NAS:FPRX, NAS:PTLA, NAS:CEMP, NAS:CHRS, NAS:HALO, OTCPK:GENSF, OTCPK:PFSCF, NAS:ACOR, NAS:DERM, OTCPK:BVNRY » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.

Ratios

vs
industry
vs
history
P/B 12.44
CLVS's P/B is ranked lower than
87% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CLVS: 12.44 )
Ranked among companies with meaningful P/B only.
CLVS' s P/B Range Over the Past 10 Years
Min: 1.28  Med: 3.97 Max: 12.8
Current: 12.44
1.28
12.8
Current Ratio 5.48
CLVS's Current Ratio is ranked higher than
56% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CLVS: 5.48 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 11.2 Max: 31.09
Current: 5.48
0.86
31.09
Quick Ratio 5.48
CLVS's Quick Ratio is ranked higher than
57% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CLVS: 5.48 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 11.2 Max: 31.09
Current: 5.48
0.86
31.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.50
CLVS's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CLVS: -13.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.9 Max: -13.5
Current: -13.5
-194.7
-13.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 59.57
CLVS's Price/Net Cash is ranked lower than
94% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. CLVS: 59.57 )
Ranked among companies with meaningful Price/Net Cash only.
CLVS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.45  Med: 11.59 Max: 61.38
Current: 59.57
2.45
61.38
Price/Net Current Asset Value 31.60
CLVS's Price/Net Current Asset Value is ranked lower than
90% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CLVS: 31.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLVS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 10.57 Max: 41.79
Current: 31.6
2.43
41.79
Price/Tangible Book 26.72
CLVS's Price/Tangible Book is ranked lower than
92% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. CLVS: 26.72 )
Ranked among companies with meaningful Price/Tangible Book only.
CLVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.39  Med: 10.54 Max: 396.95
Current: 26.72
2.39
396.95
Earnings Yield (Greenblatt) (%) -37.26
CLVS's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CLVS: -37.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -164.27  Med: 0 Max: 0
Current: -37.26
-164.27
0

More Statistics

EPS (TTM) $ -11.33
Beta1.40
Short Percentage of Float33.00%
52-Week Range $11.57 - 109.18
Shares Outstanding (Mil)38.50

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)